´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2022-09-24±³À°ÀÏÀÚ : 2022-09-24
±³À°Àå¼Ò : ºÎ»ê, º¤½ºÄÚ
±³À°ÁÖÁ¦ :
KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
ksn@ksn.or.kr ±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 23 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í [»çÀüµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-25,000/ÀüÀÏ50,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-10,000¿ø/ÀüÀÏ-20,000¿ø [ÇöÀåµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-30,000/ÀüÀÏ60,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-15,000¿ø/ÀüÀÏ-30,000¿ø *¸¸65¼¼ÀÌ»óȸ¿ø, Çлý-¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-24 Room1 08:50~09:10 Incremental hemodialysis – Pros – ÀÌÀå¿í(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 09:10~09:30 Incremental hemodialysis – Cons – ¹Ú»ï¿¤(¼øõÇâÀÇ´ë)
Åä·Ð 09-24 Room1 09:30~09:45 ÆгÎÅäÀÇ ÀüÁø¼® Çö¿µÀ²(¼øõÇâÀÇ´ë ¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 09:45~10:05 SDM-ART: ¿¬±¸ °³¿ä, ÁøÇà»óȲ ¹× ±³À° »ç·Ê ¼Ò°³ ±è¼¼Áß(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 10:05~10:25 SDM-ART: ÃßÀû »ç·Ê ¹× °³¼±»çÇ× ÅäÀÇ ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë)
Åä·Ð 09-24 Room1 10:25~10:40 ÆгÎÅäÀÇ Á¶ÀåÈñ °í°Áö(°æºÏÀÇ´ë °í·ÁÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 10:40~10:50 Break ()
±³À°½Ã°£ 09-24 Room1 10:50~11:10 Reducing the risk of intradialytic hypotension by altering the composition of the dialysate ±èÇö¿ì(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 11:10~11:30 Citrate- vs. acetate-based dialysate in hemodialysis: Clinical efficacy and safety ±è¼Ò¹Ì(´Ü±¹ÀÇ´ë)
Åä·Ð 09-24 Room1 11:30~11:45 ÆгÎÅäÀÇ ½ÅÁ¾È£±è°æ¹Î¹æ±âÅÂ(À»ÁöÀÇ´ëÀ»ÁöÀÇ´ë´©¸®³»°ú)
±³À°½Ã°£ 09-24 Room1 11:45~12:05 ÁßȯÀÚ ½ÅÀå ¿¬±¸È¸ ¹ßÀü¹æÇâ: Á¤Ã¥ ¹× ÁßȯÀÚ ÇÐȸ ¿¬°è ¹æ¾È ÀÓ¼ºÀ±(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 09-24 Room1 12:05~12:25 CRRT(continuous renal replacement therapy) ±â±â ¹× ÇÊÅÍ ±¹»êÈ ±â¼ú °³¹ß »ç¾÷ ±èµ¿±â(¼¿ïÀÇ´ë)
Åä·Ð 09-24 Room1 12:25~12:40 ÆгÎÅäÀÇ ¹éÁøÇõÀÌÇϸ°Çѽ¼®(°è¸íÀÇ´ëºÎ»êÀǴ뼿ï´ëº´¿ø)
½Ä»ç 09-24 Room1 12:40~13:40 ½Ä»ç ()
±³À°½Ã°£ 09-24 Room1 13:40~14:10 SGLT2(Sodium-glucose transport proteins)-inhibitor: endocrinologist perspective ³ëÁ¤Çö(ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø)
±³À°½Ã°£ 09-24 Room1 14:10~14:40 SGLT2(Sodium-glucose transport proteins)-inhibitor: nephrologist perspective À¯ÅÂÇö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 14:40~15:10 SGLT2(Sodium-glucose transport proteins)-inhigitor: cardiologist perspective ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
Åä·Ð 09-24 Room1 15:10~15:30 ÆгÎÅäÀÇ Áø±Ôº¹±è¿øÀÌÀº¿µ(°è¸íÀÇ´ëÀüºÏÀÇ´ë¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break ()
±³À°½Ã°£ 09-24 Room1 15:40~16:10 ¼Ò¼È³×Æ®¿öÅ· ¹× ¹Ìµð¾î ÀÌ¿ë¿¡¼ÀÇ ÀÇ·á À±¸® ±èÁ¤¾Æ(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 16:10~16:40 ÀΰøÁö´É(AI) ½Ã´ëÀÇ ÀÇ·á À±¸® ¹®Á¦ ¾ç±¤¸ð(¼¿ï»ï¼ºº´¿ø)
±³À°½Ã°£ 09-24 Room1 16:40~17:10 ÀÇ·áºÐÀï °¨Á¤ »ç¾È¿¡ ´ëÇÑ ¹ý·üÀû Çؼ® ±è¿¬Èñ(¹ý¹«¹ýÀÎ ÀǼº)
±³À°½Ã°£ 09-24 Room1 17:10~17:40 »î°ú Á×À½ÀÇ °æ°è¿¡¼ÀÇ »ý¸íÀ±¸® ¹Ú»óÀº(¾È¾ç»ùº´¿ø)
±³À°½Ã°£ 09-24 Room2 08:50~09:15 Chronic Kidney Disease °ÀºÁ¤(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 09:15~09:40 Chronic Kidney Disease-Mineral Bone Disorder ±èÁöÀº(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 09:40~10:05 ¸¶À̵¥ÀÌÅÍ Â÷ÁøÁÖ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 10:05~10:30 ¸¸¼ºÄáÆϺ´ µ¥ÀÌÅÍÀÇ Ç¥ÁØÈ¿Í ¾ÈÀüÇÑ È°¿ë ¹× º¸»ó ±èÁÖÇÑ(¼¿ïÀÇ´ë)
Åä·Ð 09-24 Room2 10:30~10:40 ÆгÎÅäÀÇ ±è°æ¹ÎÀ±¼ºÇÑ(À»ÁöÀÇ´ëâ¿øÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 09-24 Room2 10:40~10:50 Break ()
±³À°½Ã°£ 09-24 Room2 10:50~11:15 Indications of Tolvaptan Treatment in ADPKD(Autosomal dominant polycystic kidney disease) ±èÈ¿»ó(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 11:15~11:40 Tips to Improve Compliance with Tolvpatan Treatment À̹ÎÁ¤(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 11:40~12:05 Short-term Outcomes of Tolvaptan Treatment: Lessons Learned from ESSENTIAL Trial ±è¿ëö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 12:05~12:30 Hepatic Manifestation of ADPKD(Autosomal dominant polycystic kidney disease) ±èÇö¼÷(ÇѸ²ÀÇ´ë)
Åä·Ð 09-24 Room2 12:30~12:40 ÆгÎÅäÀÇ ±è¿¹´Ï¿ÀÁöÀº(°¡Å縯ÀÇ´ëÇѸ²ÀǴ뵿ź¼º½Éº´¿ø)
½Ä»ç 09-24 Room2 12:40~13:40 ½Ä»ç ()
±³À°½Ã°£ 09-24 Room2 13:40~14:05 High & Low Uric acid levels in Kidney Disease ±è±ÙÈ£(ÇѾçÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 14:05~14:30 Uric acid and Cardiometabolic SD ¹èÀºÁø(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 14:30~14:55 Best choice of ULT for Koreans ¼ÛÁ¤¼ö(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 14:55~15:20 The Effectiveness and Safety of ULT for CKD(Chronic Kidney Disease) patients ±èÁ°æ(ÇѸ²ÀÇ´ë)
Åä·Ð 09-24 Room2 15:20~15:30 ÆгÎÅäÀÇ Á¤°æȯÁ¤ÇõÁØÁ¤ÀçÇö(°æÈñÀÇ´ë°³²º´¿ø°í·ÁÀÇ´ë¾È»êº´¿ø)
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break ()
±³À°½Ã°£ 09-24 Room2 15:40~16:05 Kidney transplantation in Alport syndrome ; donor & recipient issue ½ÅÈ£½Ä(°í½ÅÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 16:05~16:30 Outcome and management of fabry disease after Kidney Transplantation ÃÖÈ«»ó(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 16:30~16:55 Consideration before kidney transplant in ADPKD(autosomal dominant polycystic kidney disease) Á¤º´ÇÏ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-24 Room2 16:55~17:20 Characteristics and management of aHUS(Atypical haemolytic-uraemic syndrome) ±è¸í±Ô(°í·ÁÀÇ´ë)
Åä·Ð 09-24 Room2 17:20~17:30 ÆгÎÅäÀÇ ¹ÎÁö¿ø¹Ú¿äÇÑȲ¼±´ö(°¡Å縯ÀÇ´ë°Ç¾çÀÇ´ëÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 08:50~09:15 Fabry disease overview-genetics and disease manifestation ±èÀ¯¹Ì(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 09:15~09:40 Renal manifestations & monitoring by nephrology ¹ÚºÀ¼ö(ÀÎÁ¦ÀÇ´ë ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 09-24 Room3 09:40~10:05 cardiac manifestations & monitoring by cardiology ±èÁöÈñ(°¡Å縯´ë ¼ººó¼¾Æ®º´¿ø)
±³À°½Ã°£ 09-24 Room3 10:05~10:30 Neurologic manifestations of Fabry disease ½ÅÁøÈï(ºÎ»êÀÇ´ë ½Å°æ°ú )
Åä·Ð 09-24 Room3 10:30~10:40 ÆгÎÅäÀÇ ¼ÕÇüÀº·ùÁ¤ÈÀÌÀº¿µ(Áß¾ÓÀÇ´ëÀÌÈÀÇ´ë¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 10:40~10:50 Break ()
±³À°½Ã°£ 09-24 Room3 10:50~11:15 ³ëÀο¡¼ ½ÅüȰµ¿ÀÌ ½Å±â´É ¾ÇÈ¿Í »ç¸Á¿¡ ¹ÌÄ¡´Â ¿µÇâ È«À¯¾Æ(°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø)
±³À°½Ã°£ 09-24 Room3 11:15~11:40 °í·ÉȯÀÚ¿¡¼ ±âÀú ½ÅÀå°æÈÁõ Á¤µµ¿¡ µû¸¥ ½ÅÀåÁúȯ ¿¹ÈÄÆò°¡ ¿¬±¸ ÀÌÇØ°æ(¼øõÇâÀÇ´ë ¼¿ïº´¿ø)
±³À°½Ã°£ 09-24 Room3 11:40~12:05 Ç÷¾× Åõ¼®À» ½ÃÀÛÇÑ ³ëÀÎ ¸¸¼ºÄáÆϺ´ ȯÀÚ¿¡¼ ½ÉÀå ±â´ÉÀÇ ¿µÇ⠺м® ±è´Ù¿î(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 12:05~12:30 ³ë³âÀÇ ÀÎÁö±â´É Àå¾Ö ¹× µðÁöÅÐ Ä¡·áÁ¦ÀÇ °³¹ß ±è¿©Áø(ÇѸ²ÀÇ´ë Ãáõ¼º½Éº´¿ø)
Åä·Ð 09-24 Room3 12:30~12:40 ÆгÎÅäÀÇ ½Å¼ºÁØÀ̵¿Çü(µ¿±¹´ëÇб³ Àϻ꺴¿ø¹üÀÏ¿¬¼¼³»°ú)
½Ä»ç 09-24 Room3 12:40~13:40 ½Ä»ç ()
±³À°½Ã°£ 09-24 Room3 13:40~14:00 Management of anemia among CKD(Chronic Kidney Disease) patients not on dialysis °íÀº½Ç(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 14:00~14:20 Management of anemia among dialysis patients ±èµµÇü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 14:20~14:45 Iron supplementation in the management of renal anemia °µ¿Çõ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 14:45~15:10 Recent updates in HIF-1a stabilizer ȲÇö¼®(°æÈñÀÇ´ë)
Åä·Ð 09-24 Room3 15:10~15:30 ÆгÎÅäÀÇ ±è¿µÈÆÀ±¼¼ÈñÁÖ¿µ¼öÁ¶¿øÁö(¾Æ»êº´¿ø°Ç¾çÀǴ뿬¼¼ÀÇ´ë°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break ()
±³À°½Ã°£ 09-24 Room3 15:40~16:05 Mechanism of urine concentration: an update ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 16:05~16:30 Function of the renal interstitium: current knowledge Á¤Áö¿ë(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 16:30~16:55 Does intensive systolic blood pressure control have similar, greater, or less cardiovascular protective effects in Korean CKD population? ±è¼¸°(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-24 Room3 16:55~17:15 Thiazide diuretics for hypertension in CKD(Chronic Kidney Disease): recent research and future directions ±è¾ç±Õ(°æÈñÀÇ´ë)
Åä·Ð 09-24 Room3 17:15~17:30 ÆгÎÅäÀÇ ±èÇü¿ì±èÇü·¡(¿¬¼¼ÀÇ´ë¼øõÇâÀÇ´ë)